BRCA1 and BRCA2 are cancer predisposition genes that are inactivated in ~25% of inherited breast cancers, ~15% of all ovarian cancers and several other cancers, suggesting that PARP inhibitors might have potential in treating a wide-range of patients with BRCA-deficient tumours [17]. The gene discussed is BRCA2; the disease is neoplasm.